<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:18:06Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/19616" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/19616</identifier><datestamp>2026-09-24T04:04:11Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Jacobs, J. Roger</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Hossain, Noor</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2016-06-22T13:47:47Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2016-06-22T13:47:47Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2010-06</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/19616</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/24761</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p> The type 1 transmembrane receptor tyrosine kinase (RTK), Neu/ErbB2 is a&#xd;
member of the Epidermal Growth Factor Receptor (EGFR) family that functions as a&#xd;
potent mediator of normal cell-growth and development. However, the aberrant&#xd;
expression of RTKs has also been implicated in many human cancers. For example, Neu&#xd;
over-expression has been implicated in human breast and ovarian cancers, and is&#xd;
correlated with poor clinical prognosis. At least one pTyr residue in Neu, Let-23, and&#xd;
PDGFR-B receptor tyrosine kinase is reported to have negative signaling capability. The&#xd;
intrinsic negative signaling behaviour of any of these pTyr residues, such as pTyr at 1028&#xd;
of Neu (NeuYA) has yet to be fully exploited with a view to better understanding of RTK&#xd;
signaling, leading to more precise knowledge in human cancer development and disease&#xd;
treatment. &lt;/p> &lt;p> Here we aimed to determine the role, specificity and the signaling pathway&#xd;
components of rat-NeuYA in Drosophila melanogaster. Specifically, we asked whether&#xd;
pTyr 1028 of Neu could affect signaling from heterologous RTKs. If so, what would be&#xd;
the pathway components? Are they already known or novel? Using a targeted&#xd;
misexpression system, such as the GAL4-Upstream Activating Sequence (GAL4-UAS)&#xd;
system, we generated graded phenotypes of various Neu alleles in adult Drosophila eye&#xd;
and wing tissues, suitable for dosage sensitive modifier screening. Taking the advantage&#xd;
of these graded phenotypes, we sought to identify and evaluate the signaling&#xd;
characteristics of Neu/ErbB2. NeuYA, in particular, suppressed the rough-eye phenotype&#xd;
of other 'add-back' Neu alleles, suggesting an inhibitory role in RTK signaling. The&#xd;
dosage sensitive modifier screen has also shown that the signal attenuating steps, such as&#xd;
receptor-mediated endocytosis, receptor recycling, and lysosomal degradation work in a&#xd;
YA-independent manner. To identify the components of the NeuYA signaling pathway in&#xd;
RTK signal attenuation, a genome-wide dominant modifier screen was undertaken to&#xd;
screen over 60,000 F1 progeny either for suppression or enhancement of the rough-eye&#xd;
phenotype of GMR-NeuYAE adults. Using deficiency mapping, we isolated and identified&#xd;
that one complementation group of suppressors to be alleles of lilliputian. Additionally,&#xd;
we narrowed down several groups of enhancers to certain deficiency regions, uncovering&#xd;
10-30 genes- previously not known to the receptor tyrosine kinase signaling pathways.&#xd;
Collectively, here we report several novel NeuYA-interactors in RTK signal attenuation in&#xd;
Drosophila. &lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">receptor tyrosince kinase</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">down-regulated pathways</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Drosophila melanogaster</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Neu alleles</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">genetic identification</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">lilliputian</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Genetic Identification of Novel Components of Receptor Yyrosine Kinase (RTK) Down-Regulation Pathways in Drosophila Melanogaster.</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>